DE69636764D1 - Zusammensetzungen zur behandlung von ischamischem gewebe - Google Patents
Zusammensetzungen zur behandlung von ischamischem gewebeInfo
- Publication number
- DE69636764D1 DE69636764D1 DE69636764T DE69636764T DE69636764D1 DE 69636764 D1 DE69636764 D1 DE 69636764D1 DE 69636764 T DE69636764 T DE 69636764T DE 69636764 T DE69636764 T DE 69636764T DE 69636764 D1 DE69636764 D1 DE 69636764D1
- Authority
- DE
- Germany
- Prior art keywords
- tissue
- ischemia
- ischemic
- ischamic
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US545998 | 1995-10-20 | ||
US08/545,998 US6121246A (en) | 1995-10-20 | 1995-10-20 | Method for treating ischemic tissue |
PCT/US1996/016723 WO1997014307A1 (en) | 1995-10-20 | 1996-10-18 | Method for treating ischemic tissue |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69636764D1 true DE69636764D1 (de) | 2007-01-25 |
DE69636764T2 DE69636764T2 (de) | 2007-10-31 |
Family
ID=24178424
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69637800T Expired - Lifetime DE69637800D1 (de) | 1995-10-20 | 1996-10-18 | Verbindungen zur Behandlung der ischaemischen Gewebe |
DE69636764T Expired - Lifetime DE69636764T2 (de) | 1995-10-20 | 1996-10-18 | Zusammensetzungen zur behandlung von ischamischem gewebe |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69637800T Expired - Lifetime DE69637800D1 (de) | 1995-10-20 | 1996-10-18 | Verbindungen zur Behandlung der ischaemischen Gewebe |
Country Status (8)
Country | Link |
---|---|
US (1) | US6121246A (de) |
EP (2) | EP0883343B1 (de) |
JP (3) | JPH11514366A (de) |
AT (2) | ATE419014T1 (de) |
AU (1) | AU725290B2 (de) |
CA (1) | CA2235372C (de) |
DE (2) | DE69637800D1 (de) |
WO (1) | WO1997014307A1 (de) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7238673B2 (en) | 1989-03-31 | 2007-07-03 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US6228844B1 (en) | 1991-11-12 | 2001-05-08 | Vical Incorporated | Stimulating vascular growth by administration of DNA sequences encoding VEGF |
US6706694B1 (en) | 1990-03-21 | 2004-03-16 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
AU7404994A (en) * | 1993-07-30 | 1995-02-28 | Regents Of The University Of California, The | Endocardial infusion catheter |
WO1995024473A1 (en) | 1994-03-08 | 1995-09-14 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US7186688B1 (en) | 1994-03-08 | 2007-03-06 | Human Genome Sciences, Inc. | Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2 |
US6040157A (en) * | 1994-03-08 | 2000-03-21 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US6608182B1 (en) | 1994-03-08 | 2003-08-19 | Human Genome Sciences, Inc. | Human vascular endothelial growth factor 2 |
US7153827B1 (en) | 1994-03-08 | 2006-12-26 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 and methods of use |
US5932540A (en) | 1994-03-08 | 1999-08-03 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US7109308B1 (en) * | 1994-03-08 | 2006-09-19 | Human Genome Sciences, Inc. | Antibodies to human vascular endothelial growth factor 2 |
US20030148968A1 (en) * | 1995-02-28 | 2003-08-07 | Hammond H. Kirk | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
KR100725199B1 (ko) * | 1995-08-29 | 2007-08-16 | 안제스에무지 가부시키가이샤 | 에이치지에프유전자를함유하는약제 |
WO1997029701A1 (en) | 1996-02-15 | 1997-08-21 | Biosense Inc. | Catheter based surgery |
US20080305999A1 (en) * | 1996-11-01 | 2008-12-11 | John Francis Martin | Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia |
NZ336838A (en) * | 1997-01-29 | 2002-04-26 | Cornell Res Foundation Inc | A method of enhancing the level of perfusion of blood to a target tissue by administering an adenoviral vector encoded with an angiogenic peptide within 0.5-15 cm3 of the tissue |
ATE296117T1 (de) * | 1997-03-07 | 2005-06-15 | Wistar Inst | Verwendung von adenoviralen vektoren, die pdgf oder vegf exprimieren, zur heilung von gewebsdefekten und zur induzierung der hypervaskulität in säugergeweben |
US7507705B2 (en) * | 1997-10-02 | 2009-03-24 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
JP2001525173A (ja) * | 1997-12-04 | 2001-12-11 | ジェンザイム・コーポレーション | 遺伝子発現を誘導するための組成物および方法 |
DE69838526T2 (de) | 1998-02-05 | 2008-07-03 | Biosense Webster, Inc., Diamond Bar | Gerät zum Freisetzen eines Medikaments im Herzen |
US6676937B1 (en) * | 1998-03-09 | 2004-01-13 | Caritas St. Elizabeth's Medical Center Of Boston Inc. | Compositions and methods for modulating vascularization |
US20040228834A1 (en) * | 1998-03-09 | 2004-11-18 | Jeffrey Isner | Compositions and methods for modulating vascularization |
US6958147B1 (en) * | 1998-10-26 | 2005-10-25 | Licentia Ltd | Use of VEGF-C to prevent restenosis |
US7183448B2 (en) | 1998-11-13 | 2007-02-27 | Daikin Industries, Ltd. | Azeotropic composition, comprising 1, 1, 1, 3,3-pentafluoropropane and 1, 1, 1-trifluoro-3-chloro-2-propene, method of separation and purification of the same, and process for producing 1, 1, 1,3,3-pentafloropropane and 1, 1, 1-trifluoro-3-chloro-2-propene |
DE19857609A1 (de) * | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
EP1016726A1 (de) * | 1998-12-30 | 2000-07-05 | Introgene B.V. | Gentherapie zur Förderung der Angiogenesis |
US7223724B1 (en) | 1999-02-08 | 2007-05-29 | Human Genome Sciences, Inc. | Use of vascular endothelial growth factor to treat photoreceptor cells |
US6440945B1 (en) | 1999-05-27 | 2002-08-27 | Instituto Dermopatico Dell'immacolata | Method of inducing angiogenesis in nonis chemic skeletal muscle |
US20030236214A1 (en) * | 1999-06-09 | 2003-12-25 | Wolff Jon A. | Charge reversal of polyion complexes and treatment of peripheral occlusive disease |
EP1067190A1 (de) * | 1999-07-09 | 2001-01-10 | Introgene B.V. | Gentherapie zur Erhöhung und/oder Induktion der Angiogenese |
EP1132098B1 (de) * | 1999-09-21 | 2010-05-26 | AnGes MG, Inc. | Gentherapie für zerebrale gefässerkrankungen |
WO2001026694A1 (fr) | 1999-10-08 | 2001-04-19 | Medgene Bioscience, Inc. | Therapie genique pour cardiomyopathie |
ATE409494T1 (de) * | 1999-10-29 | 2008-10-15 | Anges Mg Inc | Gentherapie für diabetische ischämie |
US6748258B1 (en) * | 1999-11-05 | 2004-06-08 | Scimed Life Systems, Inc. | Method and devices for heart treatment |
US6329348B1 (en) | 1999-11-08 | 2001-12-11 | Cornell Research Foundation, Inc. | Method of inducing angiogenesis |
US20040072785A1 (en) * | 1999-11-23 | 2004-04-15 | Wolff Jon A. | Intravascular delivery of non-viral nucleic acid |
US6930089B2 (en) | 2000-02-04 | 2005-08-16 | D. Collen Research Foundation Vzw | Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic disease or stroke |
US7105168B1 (en) | 2002-06-04 | 2006-09-12 | D. Collen Research Foundation Vzw | Method of improving ischemic muscle function by administering placental growth factor |
WO2001057181A2 (en) * | 2000-02-04 | 2001-08-09 | Carmeliet, Peter | Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke |
US7727971B2 (en) | 2000-02-04 | 2010-06-01 | Life Sciences Research Partners Vzw | Use of placental growth factor for treating ischemic muscle disease |
AU6633801A (en) * | 2000-06-27 | 2002-01-08 | Medgene Bioscience Inc | Medicinal compositions for angiogenic therapy |
US7273751B2 (en) * | 2000-08-04 | 2007-09-25 | Human Genome Science, Inc. | Vascular endothelial growth factor-2 |
WO2002031138A1 (fr) * | 2000-10-06 | 2002-04-18 | Dnavec Research Inc. | Vecteur de paramyxovirus permettant de transferer un gene etranger dans le muscle squelettique |
US20040009940A1 (en) * | 2000-10-20 | 2004-01-15 | Coleman Michael E. | Gene delivery formulations and methods for treatment of ischemic conditions |
JP2004527462A (ja) * | 2000-11-01 | 2004-09-09 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | 血管新生活性のinvivo刺激 |
JP2002142770A (ja) * | 2000-11-08 | 2002-05-21 | Dnavec Research Inc | 循環系への遺伝子送達用パラミクソウイルスベクター |
JP4212357B2 (ja) * | 2000-11-27 | 2009-01-21 | 株式会社ディナベック研究所 | 血管新生遺伝子をコードするパラミクソウイルスベクターおよびその利用 |
US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
US20020168739A1 (en) * | 2001-03-09 | 2002-11-14 | Wu Kenneth K. | Vectors, compositions and methods for treating a vascular disorder |
US20020131959A1 (en) * | 2001-03-14 | 2002-09-19 | Ivo Buschmann | Means and methods for the modulation of arteriogenesis |
US20020192688A1 (en) * | 2001-04-05 | 2002-12-19 | Xiaoming Yang | Imaging nucleic acid delivery |
ATE470676T1 (de) * | 2001-04-13 | 2010-06-15 | Human Genome Sciences Inc | Anti-vegf-2 antikörper |
AU2002252631A1 (en) * | 2001-04-13 | 2002-10-28 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US20050232921A1 (en) * | 2001-04-13 | 2005-10-20 | Rosen Craig A | Vascular endothelial growth factor 2 |
US7182944B2 (en) * | 2001-04-25 | 2007-02-27 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of increasing distribution of nucleic acids |
DE10122855A1 (de) * | 2001-05-11 | 2002-11-14 | Max Planck Gesellschaft | Mittel zur Verbesserung der Gewebepenetration |
EP1581241A4 (de) * | 2001-06-20 | 2005-11-09 | Ludwig Inst Cancer Res | Stimulation von vaskularisierung mit vegf-b |
US7217570B2 (en) * | 2001-08-23 | 2007-05-15 | The Wistar Institute Of Anatomy And Biology | Organotypic intestinal culture and methods of use thereof |
US20040031067A1 (en) * | 2001-10-11 | 2004-02-12 | Meenhard Herlyn | Regulation of human skin healing |
KR100562824B1 (ko) | 2002-03-20 | 2006-03-23 | 주식회사 바이로메드 | 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자 |
PL195457B1 (pl) * | 2002-08-05 | 2007-09-28 | Zaklady Farm Polpharma Sa | Kaseta ekspresyjna, dwucistronowy wektor plazmidowy, środek farmaceutyczny oraz ich zastosowanie |
US20140170116A9 (en) * | 2002-08-22 | 2014-06-19 | Marc S. Penn | Method of treating ischemic disorders |
US20050271639A1 (en) * | 2002-08-22 | 2005-12-08 | Penn Marc S | Genetically engineered cells for therapeutic applications |
US7785601B2 (en) | 2002-12-31 | 2010-08-31 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
US6817068B2 (en) * | 2003-01-02 | 2004-11-16 | The Burton Corporation | Adjustable length strap assembly |
WO2004098534A2 (en) * | 2003-02-24 | 2004-11-18 | Therion Biologics Corporation | Methods for delivering angiogenic modulators using pox viruses |
CA2557737C (en) * | 2003-03-12 | 2014-08-05 | Advisys, Inc. | Insulin-like growth factor (igf-i) plasmid-mediated supplementation for therapeutic applications |
MXPA05010345A (es) * | 2003-03-27 | 2006-03-08 | Johnson & Johnson | Uso de la eritropoyetina en la recuperacion del accidente cerebrovascular. |
KR20060052692A (ko) * | 2003-06-05 | 2006-05-19 | 센텔리옹 에스아에스 | 고콜레스테롤혈증 또는 당뇨병과 관련된 혈관형성 결함을치료하기 위한 섬유모세포 성장 인자를 코딩하는플라스미드 |
US7794713B2 (en) | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
US7862812B2 (en) | 2006-05-31 | 2011-01-04 | Lpath, Inc. | Methods for decreasing immune response and treating immune conditions |
US8895303B2 (en) | 2006-11-13 | 2014-11-25 | Charite-Universitatsmedizin Berlin | Method of cell culture and method of treatment comprising a vEPO protein variant |
EP2036571A1 (de) | 2007-09-13 | 2009-03-18 | Sygnis Bioscience GmbH & Co. KG | Verwendung von G-CSF für die Behandlung von Schlaganfall |
WO2009079451A2 (en) * | 2007-12-14 | 2009-06-25 | The Cleveland Clinic Foundation | Compositions and methods of promoting wound healing |
US20090202606A1 (en) * | 2008-01-25 | 2009-08-13 | Viromed Co., Ltd. | Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor |
BRPI0911511B8 (pt) * | 2008-04-09 | 2021-05-25 | Helixmith Co Ltd | formulação de dna liofilizadas para aumentar a expressão de dna de plasmídeo |
CN102740894B (zh) | 2009-08-28 | 2015-07-15 | 克利夫兰临床医学基金会 | 用于治疗缺血组织的sdf-1递送 |
WO2011054829A1 (en) * | 2009-11-03 | 2011-05-12 | Roche Diagnostics Gmbh | NT-pro ANP AND SFlt-1 FOR THE DIFFERENTIATION BETWEEN CIRCULATORY AND ISCHEMIC EVENTS |
WO2014138793A1 (en) | 2013-03-13 | 2014-09-18 | The University Of Queensland | A method of isolating cells for therapy and prophylaxis |
SG11201602452SA (en) | 2013-10-22 | 2016-05-30 | Viromed Co Ltd | Composition for preventing or treating amyotrophic lateral sclerosis using two or more isoforms of hepatocyte growth factor |
KR20210027493A (ko) | 2018-07-19 | 2021-03-10 | 주식회사 헬릭스미스 | 네이키드 dna 유전자 요법을 위한 동결 건조된 약제학적 조성물 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE277193T1 (de) * | 1989-03-21 | 2004-10-15 | Vical Inc | Expression von exogenen polynukleotidsequenzen in wirbeltieren |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5693622A (en) * | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
US5328470A (en) * | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
JPH06509329A (ja) * | 1991-06-28 | 1994-10-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 細胞の部位特異的な点滴注入または細胞の部位特異的形質転換による疾患の治療およびそのためのキット |
US5661133B1 (en) * | 1991-11-12 | 1999-06-01 | Univ Michigan | Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein |
AU694097B2 (en) * | 1992-11-18 | 1998-07-16 | Arch Development Corporation | Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle |
US5593972A (en) * | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
WO1994025056A2 (en) * | 1993-04-29 | 1994-11-10 | Washington University | Use of platelet-derived growth factor to improve collateral circulation |
US5792453A (en) * | 1995-02-28 | 1998-08-11 | The Regents Of The University Of California | Gene transfer-mediated angiogenesis therapy |
-
1995
- 1995-10-20 US US08/545,998 patent/US6121246A/en not_active Expired - Lifetime
-
1996
- 1996-10-18 EP EP96936690A patent/EP0883343B1/de not_active Expired - Lifetime
- 1996-10-18 JP JP9516039A patent/JPH11514366A/ja not_active Withdrawn
- 1996-10-18 AT AT05270064T patent/ATE419014T1/de not_active IP Right Cessation
- 1996-10-18 AU AU74548/96A patent/AU725290B2/en not_active Ceased
- 1996-10-18 CA CA002235372A patent/CA2235372C/en not_active Expired - Fee Related
- 1996-10-18 DE DE69637800T patent/DE69637800D1/de not_active Expired - Lifetime
- 1996-10-18 AT AT96936690T patent/ATE347910T1/de not_active IP Right Cessation
- 1996-10-18 WO PCT/US1996/016723 patent/WO1997014307A1/en active IP Right Grant
- 1996-10-18 EP EP05270064A patent/EP1625858B1/de not_active Expired - Lifetime
- 1996-10-18 DE DE69636764T patent/DE69636764T2/de not_active Expired - Lifetime
-
2007
- 2007-10-02 JP JP2007259278A patent/JP2008024718A/ja not_active Withdrawn
-
2011
- 2011-08-09 JP JP2011174322A patent/JP2011219502A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JPH11514366A (ja) | 1999-12-07 |
EP1625858A1 (de) | 2006-02-15 |
WO1997014307A1 (en) | 1997-04-24 |
US6121246A (en) | 2000-09-19 |
AU7454896A (en) | 1997-05-07 |
EP0883343B1 (de) | 2006-12-13 |
ATE347910T1 (de) | 2007-01-15 |
ATE419014T1 (de) | 2009-01-15 |
EP0883343A4 (de) | 2002-04-10 |
DE69636764T2 (de) | 2007-10-31 |
DE69637800D1 (de) | 2009-02-12 |
CA2235372C (en) | 2009-01-27 |
CA2235372A1 (en) | 1997-04-24 |
JP2008024718A (ja) | 2008-02-07 |
JP2011219502A (ja) | 2011-11-04 |
AU725290B2 (en) | 2000-10-12 |
EP0883343A1 (de) | 1998-12-16 |
EP1625858B1 (de) | 2008-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69636764D1 (de) | Zusammensetzungen zur behandlung von ischamischem gewebe | |
DE69523074D1 (de) | Verfahren zur behandlung von implantierbaren biologischen geweben zur verringerung von verkalkung | |
DE69434431D1 (de) | Methoden zur behandlung von muskelerkrankungen und muskelstörungen | |
DE69027865D1 (de) | ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN | |
EA200300845A1 (ru) | Модифицированные антитела и способы применения | |
EA199801044A1 (ru) | Модуляторы регенерации тканей | |
BR9915573A (pt) | Processo de preparação de uma composição protéica e uma fórmula infantil contendo a mesma | |
ATE330631T1 (de) | Antikörperfragmente zur lokalen behandlung von augenerkrankungen | |
ATE177954T1 (de) | Verfahren zur behandlung von knochengeweben und implantierbare biomaterialien dafür | |
FI900808A0 (fi) | Humant mannos bindande protein. | |
DE3856594D1 (de) | Mittel zur behandlung der alzheimer-krankheit | |
EP1420031A3 (de) | Morphogenetisches Protein der Knochen, BMP-18, und deren Zusammensetzungen | |
DE69032200D1 (de) | Verfahren zur Behandlung von Schnittblumen | |
ATE422357T1 (de) | Verwendung von allopurinol zur behandlung von bluthochdruck | |
DE69835680D1 (de) | Therapeutische verwendung von smr1 protein und seinen aktiven derivaten | |
ATE484294T1 (de) | Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen | |
ATE251886T1 (de) | Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit | |
EA200001124A1 (ru) | Способ генной терапии | |
ATE165008T1 (de) | Methode zur behandlung intestinaler krankheiten | |
DE69932922D1 (de) | Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen | |
ATE251462T1 (de) | Verfahren zur behandlung von narbengewebe | |
DE69920015D1 (de) | Verfahren zur induktion der herstellung von wachstumsfaktoren | |
ATE306278T1 (de) | Behandlung von knochenleiden mit adrenomedullin | |
DE69307702D1 (de) | Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit | |
DE60119285D1 (de) | Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8330 | Complete renunciation |